Evidence map›Paper›PMID 39408311›Full record

ArticleNutrients2024

Effect of Obesity and Metabolic Health Status on Metabolic-Associated Steatotic Liver Disease among Renal Transplant Recipients Using Hepatic Steatosis Index.

I-Hsin Lin, Yi-Ping Yu, Tuyen Van Duong, Shih-Wei Nien, I-Hsin Tseng, Yi-Ming Wu, Yang-Jen Chiang, Chia-Yu Chiang, Chia-Hui Chiu, Ming-Hsu Wang and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Nutrients, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

I-Hsin LinDepartment of Medical Nutrition Therapy, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.ORCID 0000-0001-8056-9106
Yi-Ping YuDepartment of Nutrition and Health Sciences, Chinese Culture University, Taipei 111, Taiwan.
Tuyen Van DuongSchool of Nutrition and Health Sciences, College of Nutrition, Taipei Medical University, Taipei 110, Taiwan.ORCID 0000-0002-2287-0723
Shih-Wei NienDepartment of Medical Nutrition Therapy, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
I-Hsin TsengDepartment of Medical Nutrition Therapy, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Yi-Ming WuDepartment of Medical Nutrition Therapy, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Yang-Jen ChiangDepartment of Urology, Linkou Chang Gung Memorial Hospital, Taoyuan 333, Taiwan.
Chia-Yu ChiangDepartment of Business Administration, College of Management, National Changhua University of Education, Changhua 500, Taiwan.
Chia-Hui ChiuCenter for General Education, Taipei Medical University, Taipei 110, Taiwan.
Ming-Hsu WangCenter for General Education, Taipei Medical University, Taipei 110, Taiwan.
Nien-Chieh YangDepartment of Nutrition and Health Sciences, Chinese Culture University, Taipei 111, Taiwan.
Ta-Ho WuDepartment of Nutrition and Health Sciences, Chinese Culture University, Taipei 111, Taiwan.
Te-Chih WongDepartment of Nutrition and Health Sciences, Chinese Culture University, Taipei 111, Taiwan.ORCID 0000-0002-5798-1060

Funding

Chang Gung Memorial Hospital CMRPG3N0781National Science and Technology Council 111-2320-B-034002-
6 · The paper itself

Abstract

BACKGROUND/

objectivesObesity and metabolic conditions increase the risk of metabolic-associated steatotic liver disease (MASLD). This study examined the risk of MASLD in 137 renal transplant recipients (RTRs) from a single-center hospital on the basis of their obesity and metabolic health status.

methodsParticipants were categorized into four groups: metabolically healthy nonobese (MHNO), metabolically healthy obese (MHO), metabolically abnormal nonobese (MANO), and metabolically abnormal obese (MAO). MASLD was assessed using the hepatic steatosis index (HSI), calculated as 8 × (aspartate aminotransferase/alanine aminotransferase ratio) + body mass index + 2 (if diabetic) + 2 (if woman). The HSI scores were 29.50 ± 4.55, 38.08 ± 5.44, 33.61 ± 5.23, and 39.86 ± 4.13 in the MHNO, MHO, MANO, and MAO groups, respectively (

resultsOverall, 25.55% of the participants (57.14% men) were classified as having MASLD (HSI > 36). A multivariate-adjusted regression analysis revealed significantly higher HSI scores in the MAO group than in the MHNO group. Both MHO and MANO groups also had significantly higher HSI scores. The odds ratios for more severe MASLD were 2.74 (95% CI: 0.88-8.52) for the MANO group and 74.59 (95% CI: 13.29-418.68) for the MAO group compared with the MHNO group.

conclusionsThese findings suggest that RTRs with obesity have a higher risk of MASLD, but even those with a normal weight and metabolic abnormalities are at increased risk.

Indexed as

Body Mass IndexKidney TransplantationObesityAdultAlanine TransaminaseAspartate AminotransferasesCross-Sectional StudiesFatty LiverFemaleHumansMaleMiddle AgedNon-alcoholic Fatty Liver DiseaseRisk FactorsTransplant RecipientsAlanine TransaminaseAspartate Aminotransferasesmetabolically healthy obesemetabolic-associated fatty liver diseaserenal transplant recipients

Identifiers

PMID39408311
PMCPMC11478899

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.